Indústrias
Pharma Manufacturing Outsourcing (CDMO)
Todas as análises de Pharma Manufacturing Outsourcing (CDMO) — 4 análises.
51/100
Asymchem Laboratories: A Proven Small-Molecule CDMO in Transition to New Modalities, Already Priced for Success
Asymchem is a founder-led Chinese CDMO anchored in commercial small-molecule process chemistry, with emerging peptide, oligonucleotide and biologics work now about 30% of revenue. 2025 revenue rose 14.9% to RMB 6.67bn with adjusted net profit of RMB 1.25bn, order backlog reached US$1.385bn (+31.65%), and Q1 2026 emerging-business revenue jumped 74.1% — yet the A-share trades near 40x trailing earnings (about a 2.4% owner-earnings yield), while founder-concentrated governance and the BIOSECURE policy overhang cap the multiple. Rating Hold: a high-quality chemistry franchise whose new-modality transition is real, but the current price already pays for most of the 2026 recovery; the ideal buy zone is CNY 68-70.
48/100
48Buffett
WuXi XDC: escalando a rede de manufatura de ADC
A WuXi XDC é uma CRDMO de bioconjugados listada em Hong Kong, desmembrada do complexo WuXi, que transforma a descoberta de ADC e o trabalho de CMC em manufatura de fase tardia e comercial de maior valor, alcançando 5.94 bilhões de RMB de receita em 2025. O debate de investimento gira em torno do preço, e não da demanda por ADC: a carteira de pedidos de 2025 cresceu 50.3% para US$1.489 bilhão e a participação de mercado global subiu de 9.9% em 2022 para mais de 24%, mas a ação é negociada a cerca de 37x os lucros dos últimos 12 meses e 24x os lucros de 2026, carregando um desconto geopolítico persistente da WuXi e uma transição intensiva em capex rumo ao fornecimento comercial no exterior. Avaliação Manter: a franquia de CRDMO de ADC é forte e ainda em expansão, mas o preço atual já antecipa uma grande parcela da próxima etapa comercial.
52/100
56Buffett
WuXi Biologics Deep Dive: A Biologics CRDMO Where Manufacturing Delivery Runs Ahead While Valuation Is Held Back by a Geopolitical Discount
WuXi Biologics is a global biologics CRDMO platform that uses a win-the-molecule model to carry early-stage programs all the way to late-stage commercial manufacturing, converting them into sticky back-end revenue. 2025 revenue reached RMB 21.79 billion, up 16.7% year on year, with back-end manufacturing already at 43.4% of revenue; yet 58.1% of revenue comes from North America, and the valuation is pinned at roughly 22x trailing earnings by a BIOSECURE-driven geopolitical discount. Rating Hold: manufacturing delivery is proven, but listing risk is not yet resolved and the margin of safety remains thin.
48/100
Lonza Group AG (LONN.SW) Zen Horizon Research Report
Lonza Group is a Basel-based Swiss biopharmaceutical CDMO founded in 1897 and now the world's second-largest biologics manufacturing outsourcer, with 2025 revenue of CHF 6.53B split between Biologics (70%, mAb / ADC / CGT / mRNA manufacturing) and Capsules & Health Ingredients (30%). The core thesis is that its 2024 strategic reset, including the USD 1.2B acquisition of Roche's Vacaville site in California, the divestiture of Specialty Ingredients, and the arrival of CEO Wolfgang Wienand, positions Lonza as one of only two scaled mammalian biologics capacity leaders above 200,000L, alongside Samsung Biologics, with additional policy tailwinds from the BIOSECURE Act against WuXi Biologics. Rating Hold: a high-quality CDMO compounder with visible recovery and upside catalysts, but a thin margin of safety at the current price.